World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
74
Citations
34596
World Ranking
1532
National Ranking
669

Medicine

D-Index
74
Citations
34785
World Ranking
19265
National Ranking
9596

Joel E. Gallant publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Joel E. Gallant sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 204 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Joel E. Gallant D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Joel E. Gallant sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 74 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Joel E. Gallant is affiliated with the Johns Hopkins University School of Medicine in the United States. Their research primarily focuses on infectious diseases, immunology, and microbiology with a strong emphasis on HIV/AIDS and related complications.

Their main fields of study include:

  • Medicine
  • Immunology and Microbiology

Subfields where they have contributed significantly include:

  • Infectious Diseases
  • Virology
  • Emergency Medicine
  • Epidemiology
  • Neurology

Joel E. Gallant has explored a variety of topics, particularly in relation to HIV/AIDS research and treatment as well as COVID-19 clinical studies. The primary topics of their work are:

  • HIV/AIDS Research and Interventions
  • HIV/AIDS Drug Development and Treatment
  • HIV Research and Treatment
  • HIV-related Health Complications and Treatments
  • HIV, Drug Use, Sexual Risk
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research

Their recent notable papers include:

  • "Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care," 2020, published in Clinical Infectious Diseases
  • "Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial," 2021, published in The Lancet HIV
  • "Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents," 2021, published in AIDS
  • "Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium," 2022, published in HIV Medicine
  • "Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium," 2021, published in The Lancet HIV

Their frequent co-authors consist of:

  • Lene Ryom
  • Kathy Petoumenos
  • Christoph Stephan
  • Antonella Castagna
  • Jens Lundgren

Joel E. Gallant has published multiple works in venues such as:

  • UNC Libraries
  • Clinical Infectious Diseases
  • The Lancet HIV
  • HIV Medicine
  • AIDS

Best Publications

  • Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy

    Diana Finzi;Monika Hermankova;Theodore Pierson;Lucy M. Carruth

  • Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

    Diana Finzi;Joel N Blankson;Janet M Siliciano;Joseph Bernard Margolick

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

    Joel E. Gallant;Schlomo Staszewski;Anton L. Pozniak;Edwin DeJesus

  • Antiretroviral Therapy for the Prevention of HIV-1 Transmission

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

    Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  • Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America

    Judith A. Aberg;Jonathan E. Kaplan;Howard Libman;Patricia Emmanuel

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F. Günthard;Michael S. Saag;Constance A. Benson;Carlos del Rio

  • Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine

    Joel E. Gallant;Richard D. Moore;Richard D. Moore;Douglas D. Richman;Douglas D. Richman;Jeanne Keruly;Jeanne Keruly

  • Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

    Judith A. Aberg;Joel E. Gallant;Khalil G. Ghanem;Patricia Emmanuel

  • Association between Adherence to Antiretroviral Therapy and Human Immunodeficiency Virus Drug Resistance

    Ajay K. Sethi;David D. Celentano;Stephen J. Gange;Richard D. Moore;Richard D. Moore

  • Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

    Beatriz Grinsztejn;Mina C. Hosseinipour;Heather J. Ribaudo;Susan Swindells

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

    Paul E. Sax;Edwin DeJesus;Anthony Mills;Andrew Zolopa

  • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

    Unknown

  • Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART

    Richard E. Nettles;Tara L. Kieffer;Tara L. Kieffer;Patty Kwon;Daphne Monie

  • Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

    Jean B. Nachega;Jean Jacques Parienti;Olalekan A. Uthman;Olalekan A. Uthman;Olalekan A. Uthman;Robert Gross

  • Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

    Joel Gallant;Adriano Lazzarin;Anthony Mills;Chloe Orkin

  • Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells

    Justin R. Bailey;Ahmad R. Sedaghat;Tara Kieffer;Timothy Brennan

  • Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

    Joel E. Gallant;Michelle A. Parish;Jeanne C. Keruly;Richard D. Moore

  • Medical Management of HIV Infection

    John G. Bartlett;Joel E. Gallant;Paul A. Pham

  • Executive Summary: Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

    Judith A. Aberg;Joel E. Gallant;Khalil G. Ghanem;Patricia Emmanuel

Frequent Co-Authors

Richard D. Moore
Richard D. Moore Johns Hopkins University
Edwin DeJesus
Edwin DeJesus Hanover University of Applied Sciences and Arts
Robert F. Siliciano
Robert F. Siliciano Johns Hopkins University School of Medicine
Richard E. Chaisson
Richard E. Chaisson Johns Hopkins University
Joseph B. Margolick
Joseph B. Margolick Johns Hopkins University
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Paul A. Volberding
Paul A. Volberding University of California, San Francisco
Eric S. Daar
Eric S. Daar Lundquist Institute
Anton Pozniak
Anton Pozniak London School of Hygiene & Tropical Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to diverse career options, many of which can be explored through related online degrees. For those interested in healthcare and patient support, pursuing programs like a child life specialist offers a fulfilling path focused on helping children cope with medical challenges.

Additionally, some online degrees cater specifically to individuals with unique circumstances. For example, the best degree for felons programs are designed to provide second chances by enabling access to education and career opportunities post-conviction.

Healthcare professionals looking to specialize might consider advanced training through functional medicine NP programs. These programs emphasize holistic approaches to care, complementing microbiology's focus on understanding pathogens and immune responses.

For those interested in the administrative and coding side of healthcare, becoming a CPC (Certified Professional Coder) opens up a career path in medical billing and coding, which plays a crucial role in healthcare systems.

Best Scientists Citing Joel E. Gallant

Trending Scientists

Recently Published Articles